This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies

This study has been withdrawn prior to enrollment.
Vaxil Therapeutics Ltd.
Information provided by:
Hadassah Medical Organization Identifier:
First received: September 11, 2005
Last updated: November 9, 2010
Last verified: September 2005


ImMucin was shown to be able to induce a robust cellular immune response mediated via both CD4+ and CD8+ T lymphocytes and therefore, could potentially be more effective in the majority of the target population.


The purpose of this study is to evaluate the safety and initial efficacy of ImMucin, a novel peptide vaccine in metastatic tumors expressing the MUC-1 Tumor Associated Antigen (TAA).

Condition Intervention Phase
Multiple Myeloma Tumors Biological: Peptide Vaccine (MUC-1) Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies

Resource links provided by NLM:

Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:
  • Determine the safety and tolerability of vaccination comprising the ImMucin vaccine
  • combined with Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), in patients
  • with multiple myeloma and other MUC-1 antigen-expressing metastatic carcinomas

Secondary Outcome Measures:
  • Determine objective anti-tumor response in patients treated with this regimen;
  • Determine immune response in patients treated with this regimen

Estimated Enrollment: 15

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All patients must have a histological or cytological diagnosis of metastatic disease expressing the MUC-1. Patients must have metastatic disease and have failed at least one regimen of standard based chemotherapy for metastatic disease such as:

    • Renal Cell Carcinoma (RCC),
    • Transitional Cell Carcinoma (TCC),
    • Prostate,
    • Breast,
    • Ovary,
    • Non-small cell lung,
    • Colon,
    • Multiple myeloma and
    • Pancreatic.
  • Patients must be >18 years of age, consenting to participation in the study.
  • Patients must have at least one site of measurable tumor or measurable tumor marker.

Exclusion Criteria:

  • Patients receiving any immunosuppressive treatment that could negate development of an effective immune response to the vaccine.
  • Subjects with prior irradiation to a field that includes more than 25% of their lymph nodes and bone marrow likely to be immunosuppressed will be excluded. However, patients who had standard pelvic field radiation such as adjuvant therapy for rectal cancer are not excluded.
  • Pregnant and breast feeding women will be excluded. Premenopausal women who are not practicing or willing to practice adequate birth control methods for a period of 3 months after treatment will be excluded.
  • Patients with brain metastases.
  • Patients with active infection.
  • Patients with HIV hepatitis B surface antigen (HBS Ag) and hepatitis C virus (HCV) positive patients.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00162500

Hadassah Medical Organization
Jerusalem, Israel, 91120
Sponsors and Collaborators
Hadassah Medical Organization
Vaxil Therapeutics Ltd.
Principal Investigator: Shimon Slavin, MD Hadassah Medical Organization
  More Information Identifier: NCT00162500     History of Changes
Other Study ID Numbers: 191203-HMO-CTIL
Study First Received: September 11, 2005
Last Updated: November 9, 2010

Keywords provided by Hadassah Medical Organization:
Metastatic solid tumors

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Immunologic Factors
Physiological Effects of Drugs processed this record on July 26, 2017